Physician profile
Bachar Kassem
NPI 1548266844
$13,488.17
in general payments reported to CMS, 2019-2025
73 companies · $582 in 2025
The $582 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2020: $1,386 · 2021: $2,781 · 2022: $2,691 · 2023: $2,251 · 2024: $2,109 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,750 · Long Term Medical Supply Or Device Loan: $167 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,749.67 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,514.33 | 2019-2025 | |
| Amgen INC. | $1,263.08 | 2019-2024 | Lumakras, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $992.94 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $713.84 | 2019-2024 | Tagrisso, Enhertu, Calquence |
| Pfizer INC. | $542.33 | 2019-2025 | |
| Janssen Biotech, INC. | $539.92 | 2019-2025 | Darzalex, Imbruvica, Talvey |
| Daiichi Sankyo INC. | $475.20 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $453.77 | 2019-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $440.94 | 2019-2024 | Opdivo, Opdualag |
| Celgene Corporation | $343.86 | 2019-2024 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $338.76 | 2019-2025 | Tecentriq, Phesgo, Itovebi |
| Astellas Pharma US INC | $309.17 | 2020-2024 | Xospata, Xtandi |
| Genzyme Corporation | $231.59 | 2019-2023 | |
| Eisai INC. | $207.87 | 2019-2025 | |
| Genmab U.S., INC. | $201.82 | 2023-2025 | Tivdak |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Kassem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.